A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects

Inclusion Criteria: * Subjects with estimated glomerular filtration rate (eGFR)\< 60 mL/min/1.73m\^2 (Chronic kidney disease \[CKD\] stages 3 to 5) * Body weight \> 40 and ≤ 160 kg at screening * Male or female subject ≥ 20 years of age at screening * Not on dialysis and not expected to start dialysis during the study period * Not treated with ESAs and/or HIF-PH inhibitors within 8 weeks prior to randomization * Mean of the last 2 central laboratory Hb levels during the screening period must be ≥ 8.0 and \< 11.0 g/dL (2 measurements must be taken ≥ 2 days apart and the difference between the 2 measurements must be \< 1.2 g/dL) and the last measurements must be taken within 14 days prior to randomization * Ferritin ≥ 50 ng/mL at screening Exclusion Criteria: * New York Heart Association (NYHA) Class III or IV congestive heart failure * History of cardio- (cerebro-) vascular events (e.g., unstable angina, myocardial infarction, stroke, pulmonary thromboembolism, and acute limb ischemia) within 6 months prior to randomization * Sustained and poorly controlled arterial hypertension (defined as systolic BP≥ 180mmHg or diastolic BP ≥ 110mmHg) or hypotension (defined as systolic BP \< 90mmHg) at randomization * Proliferative choroidal or retinal disease, such as neovascular age-related macular degeneration or proliferative diabetic retinopathy requiring invasive treatment (e.g., intraocular injections or laser photocoagulation)